Manifestations of Liver Disease


Pathologic Manifestations

Congenital and acquired alterations in hepatic structure and function (acute or chronic) can be manifest by varying patterns of reaction of the liver to cell injury. Hepatocyte injury can be caused by viral infection, drugs or toxins, hypoxia, immunologic and structural disorders, or inborn errors of metabolism. The injury results in inflammatory cell infiltration and cell death (necrosis), which may be followed by a healing process of scar formation (fibrosis) and, potentially, nodule formation (regeneration). Cirrhosis is the end result of any progressive fibrotic liver disease.

Cholestasis is an alternative or concomitant response to injury caused by extrahepatic or intrahepatic obstruction to bile flow. Substances that are normally excreted in bile, such as bile acids, conjugated bilirubin, cholesterol, and trace elements, accumulate in serum. Bile pigment accumulation in liver parenchyma can be seen in liver biopsy specimens. In extrahepatic obstruction, bile pigment may be visible in the intralobular bile ducts or throughout the parenchyma as bile lakes or infarcts. In intrahepatic cholestasis, an injury to hepatocytes or an alteration in hepatic physiology leads to a reduction in the rate of secretion of solute and water. Causes include alterations in enzymatic or canalicular transporter activity, permeability of the bile canalicular apparatus, organelles responsible for bile secretion, or ultrastructure of the cytoskeleton of the hepatocyte. The end result may be clinically indistinguishable from obstructive cholestasis.

Cirrhosis, defined histologically by the presence of bands of fibrous tissue that link central and portal areas and form parenchymal nodules, is an end stage of any acute or chronic liver disease. Cirrhosis can be macronodular , with nodules of various sizes (up to 5 cm) separated by broad septa, or micronodular , with nodules of uniform size (<1 cm) separated by fine septa; mixed forms occur. The progressive scarring results in altered hepatic blood flow, with further impairment of liver cell function. Increased intrahepatic resistance to portal blood flow leads to portal hypertension.

The liver can be secondarily involved in neoplastic (metastatic) and non-neoplastic (storage diseases, fat infiltration) processes, as well as a number of systemic conditions and infectious processes. The liver can be affected by chronic passive congestion (congestive heart failure) or acute hypoxia, with hepatocellular damage.

Clinical Manifestations

Hepatomegaly

Enlargement of the liver can be caused by several mechanisms ( Table 382.1 ). Normal liver size estimations are based on age-related clinical indices, such as the degree of extension of the liver edge below the costal margin, the span of dullness to percussion, or the length of the vertical axis of the liver, as estimated from imaging techniques. In children, the normal liver edge can be felt up to 2 cm below the right costal margin. In a newborn infant, extension of the liver edge more than 3.5 cm below the costal margin in the right midclavicular line suggests hepatic enlargement. Measurement of liver span is carried out by percussing the upper margin of dullness and by palpating the lower edge in the right midclavicular line. This may be more reliable than an extension of the liver edge alone. The 2 measurements may correlate poorly.

Table 382.1
Mechanisms of Hepatomegaly
INCREASE IN THE NUMBER OR SIZE OF THE CELLS INTRINSIC TO THE LIVER
Storage
  • Fat: malnutrition, obesity, metabolic liver disease (diseases of fatty acid oxidation and Reye syndrome–like illnesses), lipid infusion (total parenteral nutrition), cystic fibrosis, medication related, pregnancy

  • Specific lipid storage diseases: Gaucher, Niemann-Pick, Wolman disease

  • Glycogen: glycogen storage diseases (multiple enzyme defects); total parenteral nutrition; infant of diabetic mother, Beckwith syndrome, poorly controlled type 1 diabetes mellitus (Mauriac syndrome)

  • Miscellaneous: α 1 -antitrypsin deficiency, Wilson disease, hypervitaminosis A

Inflammation
  • Hepatocyte enlargement (hepatitis)

    • Viral: acute and chronic

    • Bacterial: sepsis, abscess, cholangitis

    • Toxic: drugs

    • Autoimmune

  • Kupffer cell enlargement

    • Sarcoidosis

    • Systemic lupus erythematosus

    • Hemophagocytic lymphohistiocytosis

    • Macrophage activating syndrome

INFILTRATION OF CELLS
Primary Liver Tumors: Benign
  • Hepatocellular

    • Focal nodular hyperplasia

    • Nodular regenerative hyperplasia

    • Hepatocellular adenoma

  • Mesodermal

    • Infantile hemangioendothelioma

    • Mesenchymal hamartoma

  • Cystic masses

    • Choledochal cyst

    • Hepatic cyst

    • Hematoma

    • Parasitic cyst

    • Pyogenic or amebic abscess

Primary Liver Tumors: Malignant
  • Hepatocellular

    • Hepatoblastoma

    • Hepatocellular carcinoma

  • Mesodermal

    • Angiosarcoma

    • Undifferentiated embryonal sarcoma

  • Secondary or metastatic processes

    • Lymphoma

    • Leukemia

    • Lymphoproliferative disease

    • Langerhans cell histiocytosis

    • Neuroblastoma

    • Wilms tumor

INCREASED SIZE OF VASCULAR SPACE
  • Intrahepatic obstruction to hepatic vein outflow

    • Venoocclusive disease

    • Hepatic vein thrombosis (Budd-Chiari syndrome)

    • Hepatic vein web

  • Suprahepatic

    • Congestive heart failure

  • Pericardial disease/tamponade/constrictive pericarditis

  • Post-Fontan procedure

  • Hematopoietic: sickle cell anemia, thalassemia

INCREASED SIZE OF BILIARY SPACE
  • Congenital hepatic fibrosis

  • Caroli disease

  • Extrahepatic obstruction

IDIOPATHIC
  • Various

    • Riedel lobe

    • Normal variant

    • Downward displacement of diaphragm

The liver span increases linearly with body weight and age in both sexes, ranging from approximately 4.5-5.0 cm at 1 wk of age to approximately 7-8 cm in boys and 6.0-6.5 cm in girls by 12 yr of age. The lower edge of the right lobe of the liver extends downward (Riedel lobe) and can normally be palpated as a broad mass in some people. An enlarged left lobe of the liver is palpable in the epigastrium of some patients with cirrhosis. Downward displacement of the liver by the diaphragm (hyperinflation) or thoracic organs can create an erroneous impression of hepatomegaly.

Examination of the liver should note the consistency, contour, tenderness, and presence of any masses or bruits, as well as assessment of spleen size, along with documentation of the presence of ascites and any stigmata of chronic liver disease.

Ultrasound is useful in assessment of liver size and consistency, as well as gallbladder size. Gallbladder length normally varies from 1.5-5.5 cm (average: 3 cm) in infants to 4-8 cm in adolescents; width ranges from 0.5-2.5 cm for all ages. Gallbladder distention may be seen in infants with sepsis. The gallbladder is often absent in infants with biliary atresia.

Jaundice (Icterus)

Yellow discoloration of the sclera, skin, and mucous membranes is a sign of hyperbilirubinemia (see Chapter 123.3 ). Clinically apparent jaundice in children and adults occurs when the serum concentration of bilirubin reaches 2-3 mg/dL (34-51 µmol/L); the neonate might not appear jaundiced until the bilirubin level is >5 mg/dL (>85 µmol/L). Jaundice may be the earliest and only sign of hepatic dysfunction. Liver disease must be suspected in the infant who appears only mildly jaundiced but has dark urine or acholic (light-colored) stools. Immediate evaluation to establish the cause is required.

Measurement of the total serum bilirubin concentration allows quantitation of jaundice. Bilirubin occurs in plasma in 4 forms: unconjugated bilirubin tightly bound to albumin; free or unbound bilirubin (the form responsible for kernicterus, because it can cross cell membranes); conjugated bilirubin (the only fraction to appear in urine); and δ fraction (bilirubin covalently bound to albumin), which appears in serum when hepatic excretion of conjugated bilirubin is impaired in patients with hepatobiliary disease. The δ fraction permits conjugated bilirubin to persist in the circulation and delays resolution of jaundice. Although the terms direct and indirect bilirubin are used equivalently with conjugated and unconjugated bilirubin, this is not quantitatively correct, because the direct fraction includes both conjugated bilirubin and δ bilirubin.

Investigation of jaundice in an infant or older child must include determination of the accumulation of both unconjugated and conjugated bilirubin. Unconjugated hyperbilirubinemia might indicate increased production, hemolysis, reduced hepatic removal, or altered metabolism of bilirubin ( Table 382.2 ). Conjugated hyperbilirubinemia reflects decreased excretion by damaged hepatic parenchymal cells or disease of the biliary tract, which may be a result of obstruction, sepsis, toxins, inflammation, and genetic or metabolic disease ( Table 382.3 ).

Table 382.2
Differential Diagnosis of Unconjugated Hyperbilirubinemia
INCREASED PRODUCTION OF UNCONJUGATED BILIRUBIN FROM HEME
Hemolytic Disease (Hereditary or Acquired)
  • Isoimmune hemolysis (neonatal; acute or delayed transfusion reaction; autoimmune)

    • Rh incompatibility

    • ABO incompatibility

    • Other blood group incompatibilities

  • Congenital spherocytosis

  • Hereditary elliptocytosis

  • Infantile pyknocytosis

  • Erythrocyte enzyme defects

  • Hemoglobinopathy

    • Sickle cell anemia

    • Thalassemia

    • Others

  • Sepsis

  • Microangiopathy

    • Hemolytic-uremic syndrome

    • Hemangioma

    • Mechanical trauma (heart valve)

  • Ineffective erythropoiesis

  • Drugs

  • Infection

  • Enclosed hematoma

  • Polycythemia

    • Diabetic mother

    • Fetal transfusion (recipient)

    • Delayed cord clamping

DECREASED DELIVERY OF UNCONJUGATED BILIRUBIN (IN PLASMA) TO HEPATOCYTE
  • Right-sided congestive heart failure

  • Portacaval shunt

DECREASED BILIRUBIN UPTAKE ACROSS HEPATOCYTE MEMBRANE
  • Presumed enzyme transporter deficiency

  • Competitive inhibition

    • Breast milk jaundice

    • Lucey-Driscoll syndrome

    • Drug inhibition (radiocontrast material)

  • Miscellaneous

    • Hypothyroidism

    • Hypoxia

    • Acidosis

DECREASED STORAGE OF UNCONJUGATED BILIRUBIN IN CYTOSOL (DECREASED Y AND Z PROTEINS)
  • Competitive inhibition

  • Fever

DECREASED BIOTRANSFORMATION (CONJUGATION)
  • Neonatal jaundice (physiologic)

  • Inhibition (drugs)

  • Hereditary (Crigler-Najjar)

    • Type I (complete enzyme deficiency)

    • Type II (partial deficiency)

  • Gilbert disease

  • Hepatocellular dysfunction

ENTEROHEPATIC RECIRCULATION
  • Breast milk jaundice

  • Intestinal obstruction

    • Ileal atresia

    • Hirschsprung disease

    • Cystic fibrosis

    • Pyloric stenosis

  • Antibiotic administration

Table 382.3
Differential Diagnosis of Neonatal and Infantile Cholestasis
INFECTIOUS
  • Generalized bacterial sepsis

  • Viral hepatitis

    • Hepatitides A, B, C, D, E

    • Cytomegalovirus

    • Rubella virus

    • Herpesviruses: herpes simplex, human herpesvirus 6 and 7

    • Varicella virus

    • Coxsackievirus

    • Echovirus

    • Reovirus type 3

    • Parvovirus B19

    • HIV

    • Adenovirus

  • Others

    • Toxoplasmosis

    • Syphilis

    • Tuberculosis

    • Listeriosis

    • Urinary tract infection

TOXIC
  • Sepsis

  • Parenteral nutrition related

  • Drug, dietary supplement, herbal related

METABOLIC
  • Disorders of amino acid metabolism

    • Tyrosinemia

  • Disorders of lipid metabolism

    • Wolman disease

    • Niemann-Pick disease (type C)

    • Gaucher disease

  • Cholesterol ester storage disease

  • Disorders of carbohydrate metabolism

    • Galactosemia

    • Fructosemia

    • Glycogenosis IV

  • Disorders of bile acid biosynthesis

  • Other metabolic defects

    • α 1 -Antitrypsin deficiency

    • Cystic fibrosis

    • Hypopituitarism

    • Hypothyroidism

    • Zellweger (cerebrohepatorenal) syndrome

  • Wilson disease

  • Gestational alloimmune liver disease (previously neonatal iron storage disease )

  • Indian childhood cirrhosis/infantile copper overload

  • Congenital disorders of glycosylation

  • Mitochondrial hepatopathies

  • Citrin deficiency

GENETIC OR CHROMOSOMAL
Trisomies 17, 18, 21
INTRAHEPATIC CHOLESTASIS SYNDROMES
  • “Idiopathic” neonatal hepatitis

  • Alagille syndrome

  • Intrahepatic cholestasis (progressive familial intrahepatic cholestasis [PFIC])

    • FIC-1 deficiency

    • Bile salt export pump (BSEP) deficiency

    • MDR3 deficiency

    • Tight junction protein 2 deficiency

    • Farnesoid X receptor (FXR) mutations

  • Familial benign recurrent cholestasis associated with lymphedema (Aagenaes syndrome)

  • ARC (arthrogryposis, renal dysfunction, and cholestasis) syndrome

  • Caroli disease (cystic dilation of intrahepatic ducts)

EXTRAHEPATIC DISEASES
  • Biliary atresia

  • Sclerosing cholangitis

  • Bile duct stricture/stenosis

  • Choledochal–pancreaticoductal junction anomaly

  • Spontaneous perforation of the bile duct

  • Choledochal cyst

  • Mass (neoplasia, stone)

  • Bile/mucous plug (“inspissated bile”)

MISCELLANEOUS
  • Shock and hypoperfusion

  • Associated with enteritis

  • Associated with intestinal obstruction

  • Neonatal lupus erythematosus

  • Myeloproliferative disease (trisomy 21)

  • Hemophagocytic lymphohistiocytosis (HLH)

  • COACH syndrome (coloboma, oligophrenia, ataxia, cerebellar vermis hypoplasia, hepatic fibrosis)

  • Cholangiocyte cilia defects

Pruritus

Intense generalized itching can occur in patients with chronic liver disease often in association with cholestasis (conjugated hyperbilirubinemia). Symptoms can be generalized or localized (commonly to palms and soles), are usually worse at night, are exacerbated with stress and heat, and are relieved by cool temperatures. Pruritus is unrelated to the degree of hyperbilirubinemia; deeply jaundiced patients can be asymptomatic.

The pathogenesis of pruritus remains unknown, however, multiple suspected pruritogens have been reported including bile acids, histamine, serotonin, progesterone metabolites, endogenous opioids, the potent neuronal activator lysophosphatidic acid (LPA), and the LPA-forming enzyme, autotaxin (ATX). Ultimately, a multifactorial process is suspected as evidenced by the symptomatic relief of pruritus after administration of various therapeutic agents including bile acid-binding agents (cholestyramine), choleretic agents (ursodeoxycholic acid), opiate antagonists, antihistamines, serotonin reuptake inhibitors (sertraline), and antibiotics. Plasmapheresis, molecular adsorbent recirculating system therapy, and surgical diversion of bile (partial and total biliary diversion) have been used in attempts to provide relief for medically refractory pruritus.

Spider Angiomas

Vascular spiders (telangiectasias) , characterized by central pulsating arterioles from which small, wiry venules radiate, may be seen in patients with chronic liver disease. These are usually most prominent in the superior vena cava distribution area (on the face and chest). Their size varies between 1 and 10 mm and they exhibit central clearing with pressure. They presumably reflect altered estrogen metabolism in the presence of hepatic dysfunction.

Palmar Erythema

Blotchy erythema, most noticeable over the thenar and hypothenar eminences and on the tips of the fingers, is also noted in patients with chronic liver disease. Abnormal serum estradiol levels and regional alterations in peripheral circulation have been identified as possible causes.

Xanthomas

The marked elevation of serum cholesterol levels (to >500 mg/dL) associated with some forms of chronic cholestasis, especially Alagille syndrome, can cause the deposition of lipid in the dermis and subcutaneous tissue. Brown nodules can develop, first over the extensor surfaces of the extremities; rarely, xanthelasma of the eyelids develops.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here